Moreover, while the CD28 transmembrane portion (TM) is commonly used in CARs, CD8α TM or hinge regions have also proven advantageous in CARs against tumor antigens, and in our lab, against SARS-CoV-2 antigens [90,91]. The gene discussed is CD8A; the disease is neoplasm.